Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2016 Dec;17(1):68.
doi: 10.1186/s10194-016-0659-0. Epub 2016 Jul 30.

Long-term outcomes of occipital nerve stimulation for chronic migraine: a cohort of 53 patients

Affiliations
Observational Study

Long-term outcomes of occipital nerve stimulation for chronic migraine: a cohort of 53 patients

Sarah Miller et al. J Headache Pain. 2016 Dec.

Abstract

Background: Chronic migraine affects up to 2 % of the general population and has a substantial impact on sufferers. Occipital nerve stimulation has been investigated as a potentially effective treatment for refractory chronic migraine. Results from randomised controlled trials and open label studies have been inconclusive with little long-term data available.

Methods: The long-term efficacy, functional outcome and safety of occipital nerve stimulation was evaluated in an uncontrolled, open-label, prospective study of 53 intractable chronic migraine patients.

Results: Fifty-three patients were implanted in a single centre between 2007 and 2013. Patients had a mean age of 47.75 years (range 26-70), had suffered chronic migraine for around 12 years and had failed a mean of 9 (range 4-19) preventative treatments prior to implant. Eighteen patients had other chronic headache phenotypes in addition to chronic migraine. After a median follow-up of 42.00 months (range 6-97) monthly moderate-to-severe headache days (i.e. days on which pain was more than 4 on the verbal rating score and lasted at least 4 h) reduced by 8.51 days (p < 0.001) in the whole cohort, 5.80 days (p < 0.01) in those with chronic migraine alone and 12.16 days (p < 0.001) in those with multiple phenotypes including chronic migraine. Response rate of the whole group (defined as a >30 % reduction in monthly moderate-to-severe headache days) was observed in 45.3 % of the whole cohort, 34.3 % of those with chronic migraine alone and 66.7 % in those with multiple headache types. Mean subjective patient estimate of improvement was 31.7 %. Significant reductions were also seen in outcome measures such as pain intensity (1.34 points, p < 0.001), all monthly headache days (5.66 days, p < 0.001) and pain duration (4.54 h, p < 0.001). Responders showed substantial reductions in headache-related disability, affect scores and quality of life measures. Adverse event rates were favourable with no episodes of lead migration and only one minor infection reported.

Conclusions: Occipital nerve stimulation may be a safe and efficacious treatment for highly intractable chronic migraine patients even after relatively prolonged follow up of a median of over 3 years.

Keywords: Chronic migraine; Headache; Neurostimulation; Occipital nerve stimulation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Changes in moderate-to-severe headache days following occipital nerve stimulation. a Improvement of moderate-to-severe headache days of whole cohort over follow-up period. b Improvement in moderate-to-severe headache days of those with chronic migraine alone compared to those with multiple phenotypes over follow-up period. Table provides number of subjects included at each time point
Fig. 2
Fig. 2
Responder rates of all chronic migraine patients to prolonged occipital nerve stimulation treatment by outcome measure. Various outcome measures have been used across the occipital nerve stimulation literature to measure response in chronic migraine. The response rate of the cohort is shown for each of these outcome measures – headache days, pain intensity and a combination of headache days and/or pain intensity. VRS verbal rating scale

Similar articles

Cited by

References

    1. Aydemir N, Özkara Ç, Canbeyli R, Tekcan A. Changes in quality of life and self-perspective related to surgery in patients with temporal lobe epilepsy. Epilepsy Behav. 2004;5(5):735–742. doi: 10.1016/j.yebeh.2004.06.022. - DOI - PubMed
    1. Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache. 2003;43(4):336–342. doi: 10.1046/j.1526-4610.2003.03068.x. - DOI - PubMed
    1. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71(8):559–566. doi: 10.1212/01.wnl.0000323925.29520.e7. - DOI - PubMed
    1. Bloudek LM, Stokes M, Buse DC, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS) J Headache Pain. 2012;13(5):361–378. doi: 10.1007/s10194-012-0460-7. - DOI - PMC - PubMed
    1. Brewer AC, Trentman TL, Ivancic MG, et al. Long-term outcome in occipital nerve stimulation patients with medically intractable primary headache disorders. Neuromodulation. 2013;16(6):557–562. doi: 10.1111/j.1525-1403.2012.00490.x. - DOI - PubMed

Publication types